Feasibility of stopping paclitaxel premedication after two doses in patients not experiencing a previous infusion hypersensitivity reaction

被引：0
|
作者：
Michael J. Berger
Leslie J. Dunlea
Amy E. Rettig
Maryam B. Lustberg
Gary S. Phillips
Charles L. Shapiro
机构：
[1] The Arthur G. James Cancer Hospital and Richard J. Solove Research Institute at The Ohio State University,Pharmacy Department, The James Comprehensive Breast Center
[2] The Arthur G. James Cancer Hospital at the Ohio State University Medical Center,Medical Oncology Department, The James Comprehensive Breast Center
[3] The Arthur G. James Cancer Hospital at the Ohio State University Medical Center,Nursing Excellence, The James Comprehensive Breast Center
[4] The Ohio State University Center for Biostatistics,undefined
来源：
Supportive Care in Cancer | 2012年 / 20卷
关键词：
Abbreviated; Paclitaxel; Premedication; Prophylaxis; Hypersensitivity;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1991 / 1997
页数：6
相关论文
共 6 条
  • [1] Feasibility of stopping paclitaxel premedication after two doses in patients not experiencing a previous infusion hypersensitivity reaction
    Berger, Michael J.
    Dunlea, Leslie J.
    Rettig, Amy E.
    Lustberg, Maryam B.
    Phillips, Gary S.
    Shapiro, Charles L.
    SUPPORTIVE CARE IN CANCER, 2012, 20 (09) : 1991 - 1997
  • [2] Stopping paclitaxel premedication after two doses in patients not experiencing a previous infusion hypersensitivity reaction
    Berger, Michael J.
    Vargo, Craig
    Vincent, Mary
    Shaver, Katy
    Phillips, Gary
    Layman, Rachel
    Macrae, Erin
    Mrozek, Ewa
    Ramaswamy, Bhuvaneswari
    Wesolowski, Robert
    Shapiro, Charles L.
    Lustberg, Maryam B.
    SUPPORTIVE CARE IN CANCER, 2015, 23 (07) : 2019 - 2024
  • [3] Stopping paclitaxel premedication after two doses in patients not experiencing a previous infusion hypersensitivity reaction
    Michael J. Berger
    Craig Vargo
    Mary Vincent
    Katy Shaver
    Gary Phillips
    Rachel Layman
    Erin Macrae
    Ewa Mrozek
    Bhuvaneswari Ramaswamy
    Robert Wesolowski
    Charles L. Shapiro
    Maryam B. Lustberg
    Supportive Care in Cancer, 2015, 23 : 2019 - 2024
  • [4] Incidence of infusion hypersensitivity reaction after withholding dexamethasone premedication in early breast cancer patients not experiencing two previous cycles of infusion hypersensitivity reaction for weekly paclitaxel chemotherapy
    Parinyanitikul, Napa
    Tanpipattanakul, Walailuk
    Poovorawan, Nattaya
    Rattananupong, Thanapoom
    Laoitthi, Poranee
    Sithidetphaiboon, Piyada
    Thanasanvimon, Suebpong
    Sriuranpong, Virote
    SUPPORTIVE CARE IN CANCER, 2018, 26 (07) : 2471 - 2477
  • [5] Incidence of infusion hypersensitivity reaction after withholding dexamethasone premedication in early breast cancer patients not experiencing two previous cycles of infusion hypersensitivity reaction for weekly paclitaxel chemotherapy
    Napa Parinyanitikul
    Walailuk Tanpipattanakul
    Nattaya Poovorawan
    Thanapoom Rattananupong
    Poranee Laoitthi
    Piyada Sithidetphaiboon
    Suebpong Thanasanvimon
    Virote Sriuranpong
    Supportive Care in Cancer, 2018, 26 : 2471 - 2477
  • [6] Severe pegaspargase hypersensitivity reaction rates (grade 3) with intravenous infusion vs. intramuscular injection: analysis of 54,280 doses administered to 16,534 patients on children's oncology group (COG) clinical trials
    Burke, Michael J.
    Devidas, Meenakshi
    Maloney, Kelly
    Angiolillo, Anne
    Schore, Reuven
    Dunsmore, Kimberly
    Larsen, Eric
    Mattano, Len A., Jr.
    Salzer, Wanda
    Winter, Stuart S.
    Carroll, William
    Winick, Naomi J.
    Loh, Mignon L.
    Raetz, Elizabeth
    Hunger, Stephen P.
    Bleyer, Archie
    LEUKEMIA & LYMPHOMA, 2018, 59 (07) : 1624 - 1633
1